Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents.

@article{Schell2014MetaanalysisOI,
  title={Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents.},
  author={Ryan F Schell and Brian J. Sidone and Whitney P. Caron and Mark D. Walsh and Taylor F. White and Beth A. Zamboni and Ramesh K. Ramanathan and William C. Zamboni},
  journal={Nanomedicine : nanotechnology, biology, and medicine},
  year={2014},
  volume={10 1},
  pages={
          109-17
        }
}
UNLABELLED A meta-analysis was conducted to evaluate the inter-patient pharmacokinetic (PK) variability of liposomal and small molecule (SM) anticancer agents. Inter-patient PK variability of 9 liposomal and SM formulations of the same drug was evaluated. PK variability was measured as coefficient of variance (CV%) of area under the plasma concentration versus time curve (AUC) and the fold-difference between AUCmax and AUCmin (AUC range). CV% of AUC and AUC ranges were 2.7-fold (P<0.001) and 16… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

Clinical usefulness of liposomal formulations in cancer therapy: lessons from the experiences of doxorubicin

  • Journal of Pharmaceutical Investigation
  • 2018
VIEW 6 EXCERPTS
CITES BACKGROUND, METHODS & RESULTS
HIGHLY INFLUENCED

Ultra-High-Precision, in-vivo Pharmacokinetic Measurements Highlight the Need for and a Route Toward More Highly Personalized Medicine

Philip A. Vieira, Christina B. Shin, +5 authors Tod E. Kippin
  • Front. Mol. Biosci.
  • 2019
VIEW 2 EXCERPTS
CITES BACKGROUND

New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.

  • Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  • 2016
VIEW 2 EXCERPTS
CITES BACKGROUND

When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?

  • Drug metabolism and disposition: the biological fate of chemicals
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 50 REFERENCES

Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs

G Song
  • J Liposome Res
  • 2012
VIEW 2 EXCERPTS

Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

NM La-Beck
  • Cancer Chemotherapy Pharmacol
  • 2012

Liposomal paclitaxel formulations.

  • Journal of controlled release : official journal of the Controlled Release Society
  • 2012

A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor

SH Yang
  • Invest New Drugs
  • 2010

A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin

KK Sankhala
  • J Clin Oncol
  • 2009

Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies

WC Zamboni
  • Clin Pharmacol Ther
  • 2009
VIEW 1 EXCERPT